Orchestra BioMed Holdings, Inc. (OBIO) Financial Analysis & Valuation | Quarter Chart
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic ... more
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flag... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $335.99M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David Hochman |
| IPO Date | 2020-08-04 | CAGR | 42.48% |
| Employees | 86 | Website | orchestrabiomed.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
OBIO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $329.04M | P/E | -5.76 | Forward P/E | -3.62 | PEG | — |
| P/S | 1440971.36 | P/B | 2542696.19 | P/CF | -838777.01 | P/FCF | -779999.82 |
| Sales | $31.98M | Sales 1Y | 986.14% | Sales 3Y | 635.93% | Sales 5Y | — |
| EPS | $-0.97 | EPS 1Y | -28.57% | EPS 3Y | -19.25% | EPS 5Y | — |
| Sales QoQ | -20% | EPS QoQ | -29.63% | Sales QoQ Avg | 843.54% | EPS QoQ Avg | -147.19% |
| Gross Margin | 99.32% | Operating Margin | -181.36% | Profit Margin | -184.6% | ROCE | -56.73% |
| ROA | -51% | ROE | -133% | Altman Z Score | -2.99 | Piotroski Score | 4 |
| Current Ratio | 8.26 | Quick Ratio | 8.24 | Cash Ratio | 1.52 | Op. CF Ratio | -1.44 |
| Debt/Equity | 0.07 | Debt/Assets | 0.01 | Lt Debt/Equity | 0.03 | Lt Debt/Cap. | 0.03 |
| Intrst Cov. | -27.63 | Inventory Turnover | 0.87 | Asset Turnover | 0.28 | Receivables Turnover | 626.98 |
| Enterprise Value | $329.04M | P/E Ratio | -5.76 |
| Forward P/E | -3.62 | PEG Ratio | — |
| P/S Ratio | 1440971.36 | P/B Ratio | 2542696.19 |
| P/CF Ratio | -838777.01 | P/FCF Ratio | -779999.82 |
| EPS | $-0.97 | EPS Growth 1Y | -28.57% |
| EPS Growth 3Y | -19.25% | EPS Growth 5Y | — |
| Revenue Growth 1Y | 986.14% | Gross Margin | 99.32% |
| Operating Margin | -181.36% | Profit Margin | -184.6% |
| ROE | -133% | ROA | -51% |
| ROCE | -56.73% | Current Ratio | 8.26 |
| Quick Ratio | 8.24 | Cash Ratio | 1.52 |
| Debt/Equity | 0.07 | Interest Coverage | -27.63 |
| Altman Z Score | -2.99 | Piotroski Score | 4 |
Orchestra BioMed Holdings, Inc. (OBIO) valuation & financials
Orchestra BioMed Holdings, Inc. (OBIO) has a market capitalization of $335.99M and trades at a price-to-earnings ratio of -5.8. It operates in the Healthcare sector (Biotechnology).
Orchestra BioMed Holdings, Inc.'s revenue grew +986.1% over the last year.
Orchestra BioMed Holdings, Inc.'s next earnings report is scheduled for November 9, 2026 (provider scheduled date); analysts estimate EPS of $-0.40. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)